Josep Domingo-Domenech, MD, PhD

Josep Domingo-Domenech, MD, PhD

Contact Dr. Domingo-Domenech

233 South 10th Street
BLSB 1006
Philadelphia, PA 19107

(215) 955-3404
(215) 955-3404 fax

Medical School

MD University of Barcelona Spain - 1998
PhD University of Barcelona Spain - 2007

Residency

Residency in Medical Oncology Hospital Clinic Barcelona Spain

University Appointment

Associate Professor 2017

Research & Clinical Interest

The Domingo-Domenech laboratory main focus is to assess the molecular and cellular mechanisms of cancer, mainly in genitourinary tumors (i.e. prostate and bladder cancers). We use in vitro and in vivo mouse experimental models together with patient datasets to functionally dissect the genes and pathways involved in the initiation, therapy response and metastasis of cancer. In addition, we are investigating the cellular heterogeneity of tumors to identify the molecular pathways that allow cancer stem cells survive standard therapies. The research program comprehensively integrates experimental data using computational tools to develop novel anti-tumor therapeutic approaches and determine new molecular surrogates of clinical outcome.

The group is currently pursuing several projects:

  1. Dissect the role of GATA2 signaling network in lethal prostate cancer.
  2. Molecular characterization of Cancer Stem Cells in prostate cancer and other tumor types.
  3. Development of circulating tumor cell-patient derived xenograft (CTC-PDX) and -organoid (CTC-Org) platforms in prostate and bladder cancer, among other tumor types.
  4. Discover novel targetable pathways of bladder cancer progression to cisplatin based chemotherapy.
  5. Characterization of prostate and bladder cancer exosomes.

Dr. Domingo-Domenech is a Medical Oncologist that obtained his MD and PhD in Experimental Oncology from the University of Barcelona. During his career he has developed novel experimental models to study the aggressiveness of urologic tumors and uncovered novel cellular and molecular mechanisms contributing to therapy resistance and tumor progression of prostate cancer. He has joined the Sidney Kimmel Cancer Center at Thomas Jefferson University to lead a research program focused in deciphering the signaling networks promoting prostate and bladder cancer aggressiveness with the ultimate goal of finding new anti-cancer targets and establish new therapeutic strategies to improve cancer patient’s survival.

The Domingo-Domenech lab is a multi-disciplinary group encompassing cell biologists, molecular biologists, biochemists, urologists and medical oncologist. We collaborate with other research groups both nationally and internationally.  The lab is currently funded by grants from the NIH/NCI, Department of Defense and research foundations.

Link to lab. https://www.domingo-domenechlab.com/